Literature Scan
New and noteworthy research from the
medical literature landscape
Imatinib is Safe, Efficacious in Long-Term
Follow-Up Study
Early results (published in Leukemia
in 2009) from the phase III
International Randomized Study
of Interferon and STI571 (IRIS)
demonstrated that imatinib 400
mg once daily was more active
and associated with fewer adverse
events (AEs) than a standard
regimen of interferon alfa plus
cytarabine in patients with newly
diagnosed chronic phase (CP)
chronic myeloid leukemia (CML).
In a long-term follow-up to the
trial, Andreas Hochhaus, MD,
from the Jena University Hospital
in Germany, and co-authors
determined that the efficacy of
imatinib persisted over 10 years
with acceptable cumulative and late
toxic effects.
According to the